TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Neuroblastoma Market, by Diagnosis
6.1 Introduction
6.2 Tests
6.2.1 Bone Marrow Testing
6.2.2 Tissue Testing
6.2.3 Urine and Blood Testing
6.3 MIBG Scan
6.4 Imaging
6.5 Biopsy
Chapter 7. Global Neuroblastoma Market, by Treatment
7.1 Introduction
7.2 Medications
7.3 Surgery
7.4 Chemotherapy
7.5 Radiation therapy
7.6 Stem Cell Transplant
7.7 Immunotherapy
7.8 Monoclonal Antibody Treatment
Chapter 8. Global Neuroblastoma Market, by End-Users
8.1 Introduction
8.2 Hospitals and clinics
8.3 Ambulatory Surgical Centers
8.4 Diagnostic Centers
8.5 Research centers
8.6 Others
Chapter 9. Global Neuroblastoma Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Edwards Lifesciences Corporation
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 JenaValve Technology, Inc.
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Cigna
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Abbott
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 JC Medical, Inc.
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Medtronic
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Xeltis
11.7.1 Overview
11.7.2 Type Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Venus Medtech
11.8.1 Overview
11.8.2 Type Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 St. Jude Medical
11.9.1 Overview
11.9.2 Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 SYMETIS
11.10.1 Overview
11.10.2 Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Others
Chapter 12 Appendix
LIST OF TABLES
Table 1 Global Neuroblastoma Market Industry Synopsis, 2023-2032
Table 2 Global Neuroblastoma Market Estimates & Forecast, 2023-2032, (USD Million)
Table 3 Global Neuroblastoma Market, by Region, 2023-2032, (USD Million)
Table 4 Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 5 Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 6 Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 7 North America: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 8 North America: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 9 North America: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 10 US: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 11 US: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 12 US: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 13 Canada: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 14 Canada: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 15 Canada: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 16 South America: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 17 South America: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 18 South America: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 19 Europe: Global Neuroblastoma Market, Diagnosis, 2023-2032, (USD Million)
Table 20 Europe: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 21 Europe: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 22 Western Europe: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 23 Western Europe: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 24 Western Europe: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 25 Eastern Europe: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 26 Eastern Europe: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 27 Eastern Europe: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 28 Asia-Pacific: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 29 Asia-Pacific: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 30 Asia-Pacific: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
Table 31 Middle East & Africa: Global Neuroblastoma Market, by Diagnosis, 2023-2032, (USD Million)
Table 32 Middle East & Africa: Global Neuroblastoma Market, by Treatment, 2023-2032, (USD Million)
Table 33 Middle East & Africa: Global Neuroblastoma Market, by End-User, 2023-2032, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for the Global Neuroblastoma Market
Figure 3 Market Dynamics for the Global Neuroblastoma Market
Figure 4 Global Neuroblastoma Market Share, by diagnosis 2020
Figure 6 Global Neuroblastoma Market Share, by treatment, 2020
Figure 6 Global Neuroblastoma Market Share, by End-User, 2020
Figure 7 Global Neuroblastoma Market Share, by Region, 2020
Figure 8 North America Neuroblastoma Market Share, by Country, 2020
Figure 9 Europe Prescribed Health Apps Share, by Country, 2020
Figure 10 Asia-Pacific Neuroblastoma Market Share, by Country, 2020
Figure 11 Middle East & Africa Neuroblastoma Market Share, by Country, 2020
Figure 12 Global Neuroblastoma Market: Company Share Analysis, 2020 (%)
Figure 13 Edwards Lifesciences Corporation: Key Financials
Figure 14 Edwards Lifesciences Corporation: Segmental Revenue
Figure 15 Edwards Lifesciences Corporation: Geographical Revenue
Figure 16 JenaValve Technology, Inc.: Key Financials
Figure 17 JenaValve Technology, Inc.: Segmental Revenue
Figure 18 JenaValve Technology, Inc.: Geographical Revenue
Figure 19 Cigna: Key Financials
Figure 20 Cigna: Segmental Revenue
Figure 21 Cigna: Geographical Revenue
Figure 22 Abbott: Key Financials
Figure 23 Abbott: Segmental Revenue
Figure 24 Abbott: Geographical Revenue
Figure 25 JC Medical, Inc.: Key Financials
Figure 26 JC Medical, Inc.: Segmental Revenue
Figure 27 JC Medical, Inc.: Geographical Revenue
Figure 28 Medtronic: Key Financials
Figure 29 Medtronic: Segmental Revenue
Figure 30 Medtronic: Geographical Revenue
Figure 31 Xeltis: Key Financials
Figure 32 Xeltis: Segmental Revenue
Figure 33 Xeltis: Geographical Revenue
Figure 34 VENUS MEDTECH: Key Financials
Figure 35 VENUS MEDTECH: Segmental Revenue
Figure 36 VENUS MEDTECH: Geographical Revenue
Figure 37 St. Jude Medical: Key Financials
Figure 38 St. Jude Medical: Segmental Revenue
Figure 39 St. Jude Medical: Geographical Revenue
Figure 40 SYMETIS: Key Financials
Figure 41 SYMETIS: Segmental Revenue
Figure 42 SYMETIS: Geographical Revenue
